文献速递临床试验与 GCP基础与转化研究

恢复期血浆治疗住院COVID-19患者的随机对照试验方案

Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial.
PubMed 文献 · Trials · 2021-01-20

ConPlas-19是一项多中心、随机、开放标签、对照的2期试验,计划纳入278例无需机械通气的重症COVID-19住院成人患者,按1:1随机接受恢复期血浆单次输注联合标准治疗或仅标准治疗,主要终点为第15天进展至WHO 7分序贯量表5、6或7类的患者比例。

要点

  • 针对无需机械通气的重症COVID-19住院患者评估恢复期血浆疗效与安全性。
  • 主要终点为第15天WHO 7分序贯量表进展至5、6或7类的患者比例。
  • 计划在入组并完成D15评估达20%、40%、60%时进行疗效与无效性中期分析。

核心结论

  • 该试验旨在评估恢复期血浆被动免疫治疗住院成人COVID-19患者的疗效与安全性。

研究设计与样本

  • 多中心、随机、开放标签、对照的2期试验,计划纳入278例无需机械通气的重症COVID-19住院成人患者。
  • 受试者按1:1随机(每臂139例)并按键中心分层,接受恢复期血浆单次静脉输注联合标准治疗或仅标准治疗,随访30天。

关键数值与推荐

  • 主要终点为第15天进展至WHO 7分序贯量表5、6或7类的患者比例。
  • 计划在入组并完成D15评估达20%、40%、60%时进行疗效和/或无效性中期分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. At the time this clinical trial was planned, there were no available vaccine or therapeutic agents with proven efficacy, but the severity of the condition prompted the use of several pharmacological and non-pharmacological interventions. It has long been hypothesized that the use of convalescent plasma (CP) from infected patients who have developed an effective immune response is likely to be an option for the treatment of patients with a variety of severe acute respiratory infections (SARI) of viral etiology. The aim of this study is to assess the efficacy and safety of convalescent plasma in adult patients with severe COVID-19 pneumonia. METHODS/DESIGN: The ConPlas-19 study is a multicenter, randomized, open-label controlled trial. The study has been planned to include 278 adult patients hospitalized with severe COVID-19 infection not requiring mechanical ventilation (invasive or non-invasive). Subjects are randomly assigned in a 1:1 ratio (139 per treatment arm), stratified by center, to receive intravenously administered CP (single infusion) plus SOC or SOC alone, and are to be followed for 30 days. The primary endpoint of the study is the proportion of patients that progress to category 5, 6, or 7 (on the 7-point ordinal scale proposed by the WHO) at day 15. Interim analyses for efficacy and/or futility will be conducted once 20%, 40%, and 60% of the planned sample size are enrolled and complete D15 assessment. DISCUSSION: This clinical trial is designed to evaluate the efficacy and safety of passive immunotherapy with convalescent plasma for the treatment of adult patients hospitalized with COVID-19. The results of this study are expected to contribute to establishing the potential place of CP in the therapeutics for a new viral disease. TRIAL REGISTRATION: ClinicalTrials.gov NCT04345523 . Registered on 30 March, 2020. First posted date: April 14, 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Diago-Sempere E, Bueno JL, Sancho-López A, et al. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial. Trials. 2021. PMID: 33472681. doi:10.1186/s13063-020-05011-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。